Antibodies Archives

News and Trends 24 Aug 2015

Monoclonal Antibodies celebrate their 40th birthday, how were they discovered and changed the world?

It’s been 40 years now since the first monoclonal antibodies have been manufactured by researchers from UK’s Medical Research Council (MRC). Let’s go back to the beginning and see how they became global blockbusters. One cannot imagine today’s medical portfolio without monoclonal antibodies. Checkpoint therapies against cancer, immunosuppressives treating multiple sclerosis, vaccines against everything … […]

August 24, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 17 Aug 2015

Pfizer uses HiFiBiO’s brand-new technology to discover unique antibodies

French biotech startup HiFiBiO announced today it has achieved a milestone in its research collaboration with American giant Pfizer to develop new antibody therapeutics. The new milestone is triggering an undisclosed payment to HiFiBiO. The focus of the collaboration, originally signed in 2014, is the development and validation of HiFiBiO’s proprietary, high throughput antibody discovery platform […]

August 17, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 17 Aug 2015

Genmab’s Bispecific Antibodies Catch Another Big Fish

Genmab, the Danish company developing the DuoBody technology platform to create and develop bispecific antibody candidates, just signed another licensing agreement with a Big Pharma company. This time, Novo Nordisk has been caught in a potential $502 million (€453m) deal. The DuoBody technology involves three basic steps to generate stable bispecific human IgG1 antibodies. In the first step, […]

August 17, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 31 Jul 2015

MorphoSys Tackles the Technical Challenge of GPCR-targeted Drugs

Germany-based MorphoSys AG announced today that its partner Heptares Therapeutics, has initiated a therapeutic antibody program arising from the alliance the companies entered into in February 2013. Heptares will use MorphoSys’s antibody library to generate a new candidate targeting a GPCR, one of the largest class of pharmaceutical target currently on the market. In February 2013, MorphoSys and Heptares […]

July 31, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 29 Jul 2015

Effective Antibody from a Patient recovering from Middle East Respiratory Syndrome

Two months after the outbreak of the coronavirus in South Korea, researchers are presenting first results of an effective treatment for the Middle East Respiratory Syndrome (MERS). The Swiss biotech Humabs BioMed has been able to isolate an effective antibody from a cured patient that should now be further developed under a non-profit base. In 2012, […]

July 29, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 6 Jul 2015

ElsaLys Biotech grabs MABLife’s dual-acting antibody to treat cancer

French ElsaLys Biotech just acquired MABLife’s anti-CD160 antibody. Originally developed for the treatment of vascular eye diseases, the antibody also has the potential to be applied for tumor therapy. It inhibits vascular proliferation and modulates the immune system. To proliferate and migrate through the body, tumors rely on oxygen and nutrients supplies. Cancer cells initiate […]

July 6, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 16 Jun 2015

Novartis Uses Antibodies from Cured Patients to Fight Viruses

Novartis just paid the bill to Humabs to use its out-licensed drug candidate in a Phase II clinical trial. This monoclonal antibody was developed thanks to Humabs’ technology platform using antibodies from cured patients. Back in 2009, Humabs and Novartis entered into an exclusive licensing agreement for the use of selective human monoclonal antibodies discovered by […]

June 16, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 22 May 2015

Genzyme joins the never-ending list of Ablynx’ partners

Genzyme is joining Ablynx’ partner list, which already includes AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co, Merck Serono and Novartis. The Sanofi subsidiary now wants to try out the Nanobody technology of Ablynx against a target at the origin of multiple sclerosis. Genzyme wants to investigate nanobodies against a target that specifically aligns with Genzyme’s early-stage multiple […]

May 22, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 22 May 2015

arGEN-X’ Antibody Platform struck a new Dermatology alliance

arGEN-X and LEO Pharma allied to develop innovative antibody-based solutions for the treatment of chronic inflammation underlying many skin conditions. The deal amounts to a total of €104.5M, from which arGEN-X will receive €4.5M as an upfront payment and up to €100M in royalties. LEO Pharma will receive exclusive access to an already existing arGEN-X antibody […]

May 22, 2015 - 2 minutesmins - By Lourdes Riquelme

final sterilization proteins solution sanofi pasteur

News and Trends 16 Apr 2015

The challenge of terminal sterilization of Proteins

The production of biologicals is an important challenge for the industry. Today, very often, the only way to have a sterile final product is to, first, use sterile components and then, launch the production in a fully aseptic manufacturing facility. What if we could terminally sterilize the protein-based outcome once produced? More and more biologicals are brought to the market, […]

April 16, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 13 Apr 2015

Humabs and MedImmune partnership to develop an Influenza A treatment

Medimmune starts phase I clinical trial to investigate an antibody developed under a collaboration with Humabs BioMed for the treatment of influenza A. The novel antibody developed through Humabs’ Cellclone technology will be investigated a trial being conducted by MedImmune, the global biologics research and development arm of AstraZeneca. The investigational antibody, which has broad influenza-neutralizing […]

April 13, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 21 Mar 2015

#BioFigures: 12 Key French Players launch New Immunotechnology Reference Center MI-mabs

WHO? MI-mAbs (“MI” for Marseille Immunopole and “mAbs” for monoclonal antibody) is a new immunotechnology center headed by Prof. Francois Romagne, located at the heart of the Marseille-Luminy Scientific and Technological Park, and designed to accelerate the development of new immunotherapy antibodies against cancer and inflammatory disease. Prize-Winner of the program “Investments for the Future” […]

March 21, 2015 - 2 minutesmins - By Marie Godar

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us